Overview

Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma

Status:
Not yet recruiting

Trial end date:
2026-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the survival benefit of neoadjuvant anti-PD-1 immunotherapy plus TP chemotherapy compared with TP chemotherapy or up-front surgery in resectable locally advanced oral squamous cell carcinoma.

Phase:

Phase 3

Details

Lead Sponsor:

Hospital of Stomatology, Wuhan University

Collaborator:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Cisplatin
Docetaxel